Literature DB >> 31494944

Acid sphingomyelinase regulates TH 2 cytokine release and bronchial asthma.

Svenja Böll1,2, Sebastian Ziemann2,3, Kim Ohl1, Patricia Klemm1, Annette D Rieg2,3, Erich Gulbins4,5, Katrin Anne Becker4, Markus Kamler6, Norbert Wagner1, Stefan Uhlig2, Christian Martin2, Klaus Tenbrock1, Eva Verjans1,2.   

Abstract

BACKGROUND: Allergic diseases and especially allergic asthma are widespread diseases with high prevalence in childhood, but also in adults. Acid sphingomyelinase (ASM) is a key regulator of the sphingolipid pathway. Previous studies defined the association of ASM with the pathogenesis of TH 1-directed lung diseases like cystic fibrosis and acute lung injury. Here, we define the role of ASM in TH 2-regulated allergic bronchial asthma.
METHODS: To determine the role of Asm under baseline conditions, wild-type (WT) and Asm-/- mice were ventilated with a flexiVent setup and bronchial hyperresponsiveness was determined using acetylcholine. Flow cytometry and cytokine measurements in bronchoalveolar lavage fluid and lung tissue were followed by in vitro TH 2 differentiations with cells from WT and Asm-/- mice and blockade of Asm with amitriptyline. As proof of principle, we conducted an ovalbumin-induced model of asthma in WT- and Asm-/-  mice.
RESULTS: At baseline, Asm-/- mice showed better lung mechanics, but unaltered bronchial hyperresponsiveness. Higher numbers of Asm-/- T cells in bronchoalveolar lavage fluid released lower levels of IL-4 and IL-5, and these results were paralleled by decreased production of typical TH 2 cytokines in Asm-/- T lymphocytes in vitro. This phenotype could be imitated by incubation of T cells with amitriptyline. In the ovalbumin asthma model, Asm-/- animals were protected from high disease activity and showed better lung functions and lower levels of eosinophils and TH 2 cytokines.
CONCLUSION: Asm deficiency could induce higher numbers of TH 2 cells in the lung, but those cells release decreased TH 2 cytokine levels. Hereby, Asm-/- animals are protected from bronchial asthma, which possibly offers novel therapeutic strategies, for example, with ASM blockade.
© 2020 The Authors. Allergy published by John Wiley & Sons Ltd.

Entities:  

Keywords:  T cells; TH2; acid sphingomyelinase; allergic disease; asthmatic response

Mesh:

Substances:

Year:  2019        PMID: 31494944     DOI: 10.1111/all.14039

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  4 in total

1.  Global Trends in Research of Lipid Metabolism in T lymphocytes From 1985 to 2022: A Bibliometric Analysis.

Authors:  Peng Chen; Cheng Zhong; Shengxi Jin; Yiyin Zhang; Yirun Li; Qiming Xia; Jiaxi Cheng; Xiaoxiao Fan; Hui Lin
Journal:  Front Immunol       Date:  2022-05-26       Impact factor: 8.786

2.  Activation of Sphingomyelinase-Ceramide-Pathway in COVID-19 Purposes Its Inhibition for Therapeutic Strategies.

Authors:  Murad Abusukhun; Martin S Winkler; Stefan Pöhlmann; Onnen Moerer; Konrad Meissner; Björn Tampe; Heike Hofmann-Winkler; Michael Bauer; Markus H Gräler; Ralf A Claus
Journal:  Front Immunol       Date:  2021-12-20       Impact factor: 7.561

3.  Altered Macrophage Function Associated with Crystalline Lung Inflammation in Acid Sphingomyelinase Deficiency.

Authors:  Joanna M Poczobutt; Andrew M Mikosz; Christophe Poirier; Erica L Beatman; Karina A Serban; Fabienne Gally; Danting Cao; Alexandra L McCubbrey; Christina F Cornell; Kelly S Schweitzer; Evgeny V Berdyshev; Irina A Bronova; François Paris; Irina Petrache
Journal:  Am J Respir Cell Mol Biol       Date:  2021-05       Impact factor: 6.914

Review 4.  Acid Sphingomyelinase Deficiency: A Clinical and Immunological Perspective.

Authors:  Carolina Pinto; Diana Sousa; Vladimir Ghilas; Andrea Dardis; Maurizio Scarpa; Maria Fatima Macedo
Journal:  Int J Mol Sci       Date:  2021-11-28       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.